Drugs / MHB118C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07045454 | Mar 2025 → Mar 2029 expected | cancer | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB118C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07045454 ↗ |
| Route | Intravenous | “IV administration by Q3W” NCT07045454 ↗ |